Cargando…
17-AAG inhibits vemurafenib-associated MAP kinase activation and is synergistic with cellular immunotherapy in a murine melanoma model
Heat shock protein 90 (HSP90) is a molecular chaperone which stabilizes client proteins with important roles in tumor growth. 17-allylamino-17-demethoxygeldanamycin (17-AAG), an inhibitor of HSP90 ATPase activity, occupies the ATP binding site of HSP90 causing a conformational change which destabili...
Autores principales: | Joshi, Sandeep S., Jiang, Shunlin, Unni, Emmanual, Goding, Stephen R., Fan, Tao, Antony, Paul A., Hornyak, Thomas J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5826531/ https://www.ncbi.nlm.nih.gov/pubmed/29481571 http://dx.doi.org/10.1371/journal.pone.0191264 |
Ejemplares similares
-
The antitumor natural product tanshinone IIA inhibits protein kinase C and acts synergistically with 17-AAG
por: Lv, Chao, et al.
Publicado: (2018) -
A Smart Hyperthermia Nanofiber-Platform-Enabled Sustained Release of Doxorubicin and 17AAG for Synergistic Cancer Therapy
por: Chen, Lili, et al.
Publicado: (2021) -
Melanoma Cell Resistance to Vemurafenib Modifies Inter-Cellular Communication Signals
por: Tabolacci, Claudio, et al.
Publicado: (2021) -
Modeling tandem AAG8-MEK inhibition in melanoma cells
por: Sun, Bing, et al.
Publicado: (2014) -
Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
por: Queirolo, Paola, et al.
Publicado: (2016)